Abivax (ABVX) Reports Positive Phase 3 Maintenance Trial Results for Obefazimod in Ulcerative Colitis

ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the best up and coming stocks to buy for the next 3 years. On June 1, Abivax announced positive topline results from its Phase 3 ABTECT maintenance trial for obefazimod, an oral, first-in-class miR-124 enhancer being developed for moderately to severely active ulcerative colitis. At Week 44, both the 25 mg and 50 mg daily doses met the primary endpoint of clinical remission, with placebo-adjusted rates of 39.3% and 40.3%, respectively. Furthermore, both doses successfully met all key secondary endpoints, including endoscopic improvement and remission, demonstrating robust and durable disease control.

The trial, which involved 580 participants who were responders to prior induction therapy, showed a favorable safety profile with no new safety signals observed over the 44 weeks. These findings, combined with evidence of long-term durability from open-label extension data, support the company’s plans to submit an NDA to the US FDA for obefazimod in late Q4 2026.

Abivax (ABVX) Reports Positive Phase 3 Maintenance Trial Results for Obefazimod in Ulcerative Colitis

Pixabay/Public Domain

This milestone reinforces the potential for obefazimod to serve as a convenient, once-daily oral treatment option that could transform the standard of care for ulcerative colitis. Looking ahead, ABIVAX Société Anonyme (NASDAQ:ABVX) continues its clinical development program, with topline results from a Phase 2b induction trial for Crohn’s disease expected in mid-2027.

ABIVAX Société Anonyme (NASDAQ:ABVX) is a clinical-stage biotech company that develops therapies to stabilize immune responses in chronic inflammatory diseases. Its lead candidate, obefazimod, is currently in advanced clinical trials for the treatment of ulcerative colitis and Crohn’s disease.

While we acknowledge the risk and potential of ABVX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABVX and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1